Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
Go back to Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 40.06 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.06 | 52 Week High | $66.55 | |||
| Open | $40.06 | 52 Week Low | $37.82 | |||
| Day High | $40.06 | P/E | N/A | |||
| Day Low | $40.06 | EPS | $0.00 | |||
| Volume | 7,117 | |||||
| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 40.06 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.06 | 52 Week High | $66.55 | |||
| Open | $40.06 | 52 Week Low | $37.82 | |||
| Day High | $40.06 | P/E | N/A | |||
| Day Low | $40.06 | EPS | $0.00 | |||
| Volume | 7,117 | |||||
